[SS1] Viral ecology and characteristics of SARS-CoV-2 |
When an unknown viral pathogen such as SARS-CoV-2 which causing COVID-19, introduces to human being with public health threatening, the most important activity is understanding of the pathogenicity of the virus itself. These include host responses such as analyzing the immune status of the before and/or after infection of the pathogen. Scientific knowledge and experience with a new pathogen infection have never been explored when the virus identified. Accordingly, lessons from similar diseases that have been experienced are of useful to help understanding bran-new pathogen. In this session, the latest scientific knowledge will be discussed on the basic properties of these viruses and the characteristics of their host response to infection.
|
[SS1-1] COMPARATIVE PATHOGENESIS OF SARS, MERS and COVID-19. |
Bart L. Haagmans |
(Erasmus University Medical Centre, Netherlands) |
[SS1-2] Identification of Genes Differentially Expressed in Response to SARS-CoV-2 Infection in the Non-human Primate Model for COVID-19 |
Eun-Young Kim |
(Northwestern University, USA) |
[SS2] Medical interventions using vaccine and therapeutics |
To respond to a disaster that has not been experienced, non-medical interventions such as social distancing and wearing masks have been making great contributions to defending against the COVID-19 so far. More importantly, ultimate disease control requires medical accessibility of appropriate therapeutics and preventive vaccines to establish host defense equipment through securing immunity. In this session, the latest scientific knowledge will be discussed on the basic properties of these viruses and the characteristics of their host response to infection. In this session, a review and scientific advances of the antiviral development accomplished by the drug-repurposing strategy and the cutting-edge platforms for vaccine development technology will be discussed.
|
[SS2-1] Current status of therapeutic and virological study of SARS-CoV-2 |
Jeong-Sun Yang |
(National Institute of Health, Korea) |
[SS2-2] An inhaled corticosteroid ciclesonide is a potent blocker of SARS-CoV-2 replication |
Shutoku Matsuyama |
(National Institute of Infectious Diseases, Japan) |
[SS2-3] Spontaneous Particulate Presentation Enhances Immunogenicity of the SARS-CoV-2 RBD |
Jonathan F. Lovell |
(University at Buffalo, USA) |
[SS3] Diagnosis and response for the control of COVID-19 |
Securing fast and accurate identification of causative pathogen in order to provide scientific clues and direction in response of SARS-CoV-2 infection is the prerequisite factor for early response of the pandemic. After the identification strategy has been stable, various ways of public health response strategies have been implemented to prevent further transmission and spreading of the disease based on pathogen diagnosis and chasing. In this session, scientific bases of molecular diagnostics that played a major role in the pathogen recognition process and future direction of molecular diagnostic strategy will be discussed. In addition, successful plans and policies executed by public health authority will be pointed out in detail.
|
[SS3-1] Mass Screening in the COVID-19 Pandemic |
Nackmoon Sung |
(Clinical Research Institute, Seegene Medical Foundation, Republic of Korea) |
[SS3-2] Virologic characteristics of cases of COVID-19 in Northern Vietnam, January to May, 2020 |
Le Thi Quynh Mai |
(National Institute of Hygiene and Epidemiology, Vietnam) |
[SS3-3] Strategy and response against COVID-19 in Korea |
Jin Gwack |
(Korea Disease Control and Prevention Agency, Republic of Korea) |